

DUPLICATE

Faulding Pharmaceutical Company
A division of Mayne Pharma

May 14, 2003

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
Room 1061, HFA-305
5630 Fishers Lane
Rockville, MD 20852



Mack-Cali Centre II
650 From Road
Paramus
New Jersey 07652
United States
Telephone
+1 201 225 5500
Regulatory Facsimile
+1 201 225 5530
www.faulding.com

RE: **ANDA Citizen Petition**
Carboplatin Injection, 10 mg/mL – 60 mL Vial

Dear Sir or Madam:

The undersigned submits this Suitability Petition (the "Petition") in quadruplicate under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act and 21 CFR §10.20, 10.30, and 314.93 to request the Commissioner of the Food and Drug Administration make a determination that an Abbreviated New Drug Application may be submitted for Carboplatin Injection, 10 mg/mL in a strength of 600 mg/60 mL single use vial.

A. Action Requested

The petitioner requests that the Commissioner of the Food and Drug Administration make a determination to permit a change in the strength (total drug content) to allow for submission of an ANDA for Carboplatin Injection, 10 mg/mL, in strength of 600 mg/60 mL.

The basis of the Petition is the reference listed drug (RLD), Paraplatin[®] Injection (Paraplatin[®]), marketed by the Innovator Bristol Myers Squibb. Paraplatin[®] Injection, is available in three strengths; a single use vial containing 50 mg, 150 mg, and 450 mg of Carboplatin. Bristol Myers Squibb received approval for the product (50 mg, 150 mg, and 450 mg per vial) under the application number 019880 on March 3, 1989.

B. Statement of Grounds

Section 505(j)(2)(C) of the Food, Drug and Cosmetic Act provides for submission of an ANDA for a new drug product that differs in strength from a reference listed drug provided that FDA has approved a petition seeking permission to file such an application.

2003P.0220

CP1

Also, reference is made to FDA's approval of Citizen Petition, dated May 20, 1993 (Docket No. 92P-0467 / CP 1) allowing Faulding to file an Abbreviated New Drug Application for Carboplatin Injection 10 mg/mL in 5 mL, 15 mL, and 45 mL single –use vials (total drug content 50 mg, 150 mg, and 450 mg respectively - **Attachment 1**).

The subject of this petition for Carboplatin Injection 10 mg/mL is to permit a change in strength (total drug content) from that of reference-listed drug. The RLD, Paraplatin[®], marketed by the Innovator Bristol Myers Squibb, is a lyophilized product and available as a single use vial containing 50 mg, 150 mg, and 450 mg of Carboplatin.

The proposed drug product will be available in the same concentration, 10 mg/mL as RLD as solution in a single use vial but in strength of 600 mg/mL.

Product	Dosage Form	Route of Administration	Strength
Bristol Myers Squibb Paraplatin [®]	Lyophilized	Intravenous	Carboplatin 50 mg, 150 and 450 mg
Proposed Carboplatin Injection 10 mg/mL	Solution	Intravenous	Carboplatin 600 mg/60 mL

The proposed strength is clearly contemplated in the approved labeling of the reference listed drug. The proposed strength contains the drug amount recommended in the approved labeling for dilution with 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, to a final concentration of 0.5 mg/mL.

Paraplatin[®] is currently approved in three strengths; 50 mg, 150 mg, and 450 mg per vial. However, the approved labeling clearly contemplates that, as a single agent, it has been shown to be effective in patients with recurrent ovarian cancer at a dosage of 360 mg/m² (or 619.2 mg / 1.72 m² - Average Body Surface Area) on day 1 every 4 weeks (Dosage and Administration / Single Agent Therapy - **Attachment 4**)

The proposed strength, 600 mg/60 mL, will provide practitioners with a convenient alternative to the currently approved strengths.

The proposed strength will allow for preparation of an approved dose of 360 mg/m² by using one 600 mg/60 mL vial plus one vial of 50 mg/5 mL compared to one vial each of 50 mg, 150 mg, and 450 mg of the reference listed drug.

The proposed strength, 600 mg/60 mL, clearly conforms to the single agent therapy listed in the dosage and administration section of the approved package insert of the reference listed drug. Since the need to open multiple vials will be reduced, the proposed drug product will minimize the potential for contamination resulting from the handling of the product, such as blood borne pathogens from cut fingers and foreign particles. The proposed presentation will also provide a reduction in hazardous waste disposal and cost for the course of therapy.

The proposed drug is intended for use only as described in the **Indications and Dosage and Administration** sections of the approved labeling. Draft labeling of the proposed drug is provided in **Attachment 3**.

Included in **Attachment 4** is the package insert for Paraplatin[®], marketed by Bristol Myers Squibb. The labeling for the proposed drug is essentially identical to that of Bristol Myers Squibb's Paraplatin[®] and differs only with respect to the description of the product, the product name, inactive ingredient (mannitol), the how-supplied statement, and the specific manufacturer's information.

The proposed strength does not pose questions of safety or effectiveness because the use, doses and route of administration of the proposed product is the same as those of the reference listed drug.

To support this petition, a Medical Rationale for the proposed product (600 mg/60 mL) is provided in **Attachment 2**.

For the above reasons, the undersigned requests that the Commissioner approve this petition and find that an application for Carboplatin Injection 600 mg/60 mL is suitable for submission.

C. Environmental Impact

The petitioner claims a categorical exclusion under 21 CFR 25.31.


D. Economic Impact Statement

According to 21 CFR 10.30(b), the petitioner will, upon request by the Commissioner, submit economic impact information.

E. Certification

The undersigned certifies that, to the best knowledge and belief of the undersigned, this Petition includes all information and views on which the Petition relies, and that it includes representative data and information known to the Petitioner, which are favorable to the Petition.

Sincerely,



Aroon D. Mankad
Assistant Manager, Regulatory Affairs
Faulding Pharmaceutical Co.

Tel: (201) 225-5559
Fax: (201) 225-5530

- Attachment 1** - Suitability Petition (Docket No. 92P-0467 /CP 1)
- Attachment 2** - Medical Rationale (Carboplatin Injection 600 mg/60 mL)
- Attachment 3** - Faulding's Proposed Package Insert
- Attachment 4** - Paraplatin[®] Injection Package Insert

1

2

ATTACHMENT 1

Suitability Petition

Carboplatin Injection 10 mg/mL
(5 mL, 15 mL, and 45 mL Single-Use Vials)

Docket No. – 92P– 0467 /CP 1



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

ADMINISTRATION

Food and Drug Administration
Rockville MD 20857

DEC 27 AM 11:13

MAY 20 1993

Faulding Inc.

Agent for: David Bull Laboratories Pty. Ltd.
Attention: Josephine Dundon
200 Elmora Avenue
Elizabeth, NJ 07207

Docket No. 92P-0467/CP 1

Dear Madam:

This is in response to your petition filed on November 19, 1992, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following product: Carboplatin Injection, 10 mg/mL, in 5 mL, 15 mL, and 45 mL single-use vials (total drug content 50 mg, 150 mg, and 450 mg respectively). The listed drug product to which you refer in your petition is Paraplatin (carboplatin for injection) 50 mg, 150 mg and 450 mg/vial.

We have reviewed your petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (Act), and have determined that it is approved. This letter represents the Agency's determination that an ANDA may be submitted for the above-referenced product.

Your request involves a change in dosage form from that of the listed drug product (i.e., from lyophilized powder for reconstitution to a ready-to-use solution). The change you request is the type of change that is authorized under the Act.

Under Section 505(j)(2)(C)(i) of the Act the Agency must approve petitions seeking a dosage form which differs from the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing dosage form.

The Agency has determined that a change in dosage form (i.e., from lyophilized powder to a ready-to use solution) for the specific proposed product does not pose questions of safety or effectiveness because the uses, doses and route of administration of the proposed product are the same as those of the listed drug. The concentration of the proposed product will be the same as the final concentration of the listed drug product when reconstituted in accord with the approved labeling. Therefore, the Agency concludes that investigations are not needed in this instance. In addition, if shown to meet bioavailability requirements, the proposed product can be expected to have the same therapeutic effect as the listed reference drug.

The approval of this petition to allow an ANDA to be submitted for the above-referenced product does not mean that the Agency has determined that an ANDA will be approved for the product. The determination that an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the Agency.

For your information, the listed drug product to which you refer is covered by a period of patent protection and exclusivity which appear in Approved Drug Products With Therapeutic Equivalence Evaluations, 13th Edition, published by the Agency. The existence of exclusivity precludes submission of an ANDA until the expiration of the five year period, except that such an application may be submitted after four years if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. The existence of patent protection will require certification upon submission of an ANDA for your proposed product and may also affect the approval date of any ANDA.

To permit review of your ANDA submission you must submit all information required under Section 505(j)(2)(A) and (B) of the Act. To be approved, the product will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. We suggest that you contact the Acting Director, Division of Bioequivalence at (301) 295-8345 to determine the specific requirements for this product. During the review of your application, the Agency may require the submission of additional information.

The listed drug product to which you refer in your ANDA must be the one upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, HFD-305, Park Building, 12420 Parklawn Drive, Room 1-23, Rockville, MD 20857.

Sincerely yours,

— S —

Roger L. Williams, M.D.
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

ATTACHMENT 2

Medical Rationale

Carboplatin Injection 600 mg/60 mL

Carboplatin Injection 600 mg/60 mL

MEDICAL RATIONALE

CLINICAL PHARMACOLOGY

Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than the aquation of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.

In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 to 500 mg/m² of Paraplatin. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (N = 6), and the post distribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (N = 6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C_{max} values and areas under the plasma concentration vs. time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300-500 mg/m²).

Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days. The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine sample is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs. In patients with creatinine clearances below 60 mL/min, the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. PARAPLATIN dosages should therefore be reduced in these patients (see **DOSAGE AND ADMINISTRATION – Attachment 4**).

INDICATIONS FOR USE

Single Agent Therapy

The Package insert of the Referenced Listed Drug states that:

- Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dose of 360 mg/m² IV on day 1 every 4 weeks (**Dosage and Administration Section - Attachment 4**).
- **Use as a Single Agent for Secondary Treatment of Advanced Ovarian Cancer:** In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, PARAPLATIN (carboplatin for injection) achieved six clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks (**Comparative Toxicity Section – Attachment 4**)

Combination Therapy with Cyclophosphamide

In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin Injection 300 mg/m² IV on day 1 every four weeks for six cycles.

DOSAGE

The dosage and the rate of administration should be individualized and adjusted to desired effect to clinically relevant factors

Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dose of 360 mg/m² IV on day 1 every 4 weeks (alternatively see **Formula Dosing – Attachment 4**).

RATIONALE

The currently marketed Reference Listed Drug (RLD) is available in three different strengths (50 mg, 150 mg, and 450 mg) single use vial. As indicated in dosage and administration sections of the approved package insert of the Reference Listed Drug (Paraplatin[®]), as a single agent, it has been shown to be effective in patients with recurrent ovarian carcinoma at a dose of 360 mg/m² (equates to 619.2 mg of Carboplatin based on Average Body Surface Area 1.72 m²) by IV administration on day 1 every 4 weeks.

SUMMARY

In summary, the availability of Carboplatin Injection 600 mg/60mL in single dose vial will offer dosing flexibility, patient safety, convenience, reduction in hazardous waste, and cost saving advantage over the Reference Listed Drug

(Paraplatin®), which is currently available in 50 mg/vial, 150 mg/vial, and 450 mg/vial.

The proposed drug product presentation (600 mg/60 mL in single use vial) is intended for use only as described in the Indications and Usage and Dosage and Administration sections of Faulding's draft package insert (**Attachment 3**)

The package insert of the RLD (Bristol-Myers Squibb) is provided as Attachment II. The labeling for the proposed drug is essentially identical to that of RLD, but differs only with respect to the description of the product, the product name, inactive ingredient, the how-supplied statement and the specific manufacturer's information

We believe that the information presented in this correspondence for Carboplatin Injection 600 mg/60 mL supports our claim that the proposed presentation is suitable for a supplement to an abbreviated new drug application.

REFERENCES:

1. Package insert for Paraplatin® (Carboplatin for Injection, USP). Revised – June 2001.

**Attachment
3**

ATTACHMENT 3

Faulding's - Proposed Package Insert

Carboplatin Injection 600 mg/60 mL



Carboplatin Injection

WARNING

Carboplatin Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.


Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect.

Anaphylactic-like reactions to Carboplatin Injection have been reported and may occur within minutes of Carboplatin Injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.

DESCRIPTION

Carboplatin Injection is supplied as a sterile, aqueous solution available in 50 mg/5mL, 150 mg/15mL, 450 mg/45mL, or 600mg/60mL single-dose vials containing 10 mg/mL of carboplatin for administration by intravenous infusion. Each mL contains 10 mg carboplatin and Water for Injection, USP.

Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0]-, (SP-4-2), and has the following structural formula:



Carboplatin is a crystalline powder with the molecular formula of $C_6H_{12}N_2O_4Pt$ and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5-7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide.

CLINICAL PHARMACOLOGY

Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The

aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.

In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 to 500 mg/m² of Carboplatin Injection. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (N=6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (N=6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C_{max} values and areas under the plasma concentration vs. time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 - 500 mg/m²).

Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.

The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.

In patients with creatinine clearances below 60 mL/min the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin Injection dosages should therefore be reduced in these patients (see **DOSAGE AND ADMINISTRATION**).

The primary determinant of Carboplatin Injection clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see **DOSAGE AND ADMINISTRATION**) to provide predictable Carboplatin Injection plasma AUCs should be used in elderly patients to minimize the risk of toxicity.

CLINICAL STUDIES

Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), 789 chemotherapy naive patients with advanced ovarian cancer were treated with Carboplatin Injection or cisplatin, both in combination with cyclophosphamide every 28 days for six courses before surgical reevaluation. The following results were obtained from both studies:

Comparative Efficacy

Overview of Pivotal Trials

	NCIC	SWOG
Number of patients randomized	447	342
Median age (years)	60	62
Dose of cisplatin	75 mg/m ²	100 mg/m ²
Dose of carboplatin	300 mg/m ²	300 mg/m ²
Dose of Cyclophosphamide	600 mg/m ²	600 mg/m ²
Residual tumor <2 cm (number of patients)	39% (174/447)	14% (49/342)

Clinical Response in Measurable Disease Patients

	NCIC	SWOG
Carboplatin (number of patients)	60% (48/80)	58% (48/83)
Cisplatin (number of patients)	58% (49/85)	43% (33/76)
95% C.I. of difference (Carboplatin – Cisplatin)	(-13.9%, 18.6%)	(-2.3%, 31.1%)

Pathologic Complete Response*

	NCIC	SWOG
Carboplatin (number of patients)	11% (24/224)	10% (17/171)
Cisplatin (number of patients)	15% (33/223)	10% (17/171)
95% C.I. of difference (Carboplatin – Cisplatin)	(-10.7%, 2.5%)	(-6.9%, 6.9%)

*114 Carboplatin and 109 Cisplatin patients did not undergo second look surgery in NCIC study. 90 Carboplatin and 106 Cisplatin patients did not undergo second look surgery in SWOG study.

Progression-Free Survival (PFS)

	NCIC	SWOG
Median		
Carboplatin	59 weeks	49 weeks
Cisplatin	61 weeks	47 weeks
2-Year PFS*		
Carboplatin	31%	21%
Cisplatin	31%	21%
95% C.I. of difference (Carboplatin – Cisplatin)	(-9.3, 8.7)	(-9.0, 9.4)
3-Year PFS*		
Carboplatin	19%	8%
Cisplatin	23%	14%
95% C.I. of difference (Carboplatin – Cisplatin)	(-11.5, 4.5)	(-14.1, 0.3)

Hazard ratio**	1.10	1.02
95% C.I.	(0.89, 1.35)	(0.81, 1.29)
(Carboplatin – Cisplatin)		

- * Kaplan-Meier Estimates
Unrelated deaths occurring in the absence of progression were counted as events (progression) in this analysis.
- ** Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.

	Survival NCIC	SWOG
Median		
Carboplatin	110 weeks	86 weeks
Cisplatin	99 weeks	79 weeks
 2-Year Survival*		
Carboplatin	51.9%	40.2%
Cisplatin	48.4%	39.0%
95% C.I. of difference (Carboplatin – Cisplatin)	(-6.2, 13.2)	(-9.8, 12.2)
 3-Year Survival*		
Carboplatin	34.6%	18.3%
Cisplatin	33.1%	24.9%
95% C.I. of difference (Carboplatin – Cisplatin)	(-7.7, 10.7)	(-15.9, 2.7)
 Hazard Ratio**	0.98	1.01
95% C.I.	(0.78, 1.23)	(0.78, 1.30)
(Carboplatin – Cisplatin)		

- * Kaplan-Meier Estimates
- ** Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.

Comparative Toxicity: The pattern of toxicity exerted by the Carboplatin Injection-containing regimen was significantly different from that of the cisplatin-containing combinations. Differences between the two studies may be explained by different cisplatin dosages and by different supportive care.

The Carboplatin Injection-containing regimen induced significantly more thrombocytopenia and, in one study, significantly more leukopenia and more need for transfusional support. The cisplatin-containing regimen produced significantly more anemia in one study. However, no significant differences occurred in incidences of infections and hemorrhagic episodes.

Non-hematologic toxicities (emesis, neurotoxicity, ototoxicity, renal toxicity, hypomagnesemia, and alopecia) were significantly more frequent in the cisplatin-containing arms.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY				
		Carboplatin Arm Percent*	Cisplatin Arm Percent	P-Values**
Bone Marrow				
Thrombocytopenia	<100,000/mm ³	70	29	<0.001
	<50,000/mm ³	41	6	<0.001
Neutropenia	<2000 cells/mm ³	97	96	n.s.
	<1000 cells/mm ³	81	79	n.s.
Leukopenia	<4000 cells/mm ³	98	97	n.s.
	<2000 cells/mm ³	68	52	0.001
Anemia	<11g/dL	91	91	n.s.
	<8 g/dL	18	12	n.s.
Infections		14	12	n.s.
Bleeding		10	4	n.s.
Transfusions		42	31	0.018
Gastrointestinal				
Nausea and vomiting		93	98	0.010
Vomiting		84	97	<0.001
Other GI side effects		50	62	0.013
Neurologic				
Peripheral neuropathies		16	42	<0.001
Ototoxicity		13	33	<0.001
Other sensory side effects		6	10	n.s.
Central neurotoxicity		28	40	0.009
Renal				
Serum creatinine elevations		5	13	0.006
Blood urea elevations		17	31	<0.001
Hepatic				
Bilirubin elevations		5	3	n.s.
SGOT elevations		17	13	n.s.
Alkaline phosphatase elevations		-	-	-
Electrolytes loss				
Sodium		10	20	0.005
Potassium		16	22	n.s.
Calcium		16	19	n.s.
Magnesium		63	88	<0.001
Other side effects				
Pain		36	37	n.s.
Asthenia		40	33	n.s.
Cardiovascular		15	19	n.s.
Respiratory		8	9	n.s.
Allergic		12	9	n.s.
Genitourinary		10	10	n.s.
Alopecia +		50	62	0.017
Mucositis		10	9	n.s.

* Values are in percent of evaluable patients

** n.s.= not significant, p>0.05

+ May have been affected by cyclophosphamide dosage delivered

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY				
		Carboplatin Arm Percent*	Cisplatin Arm Percent	P-Values**
Bone Marrow				
Thrombocytopenia	<100,000/mm ³	59	35	<0.001
	<50,000/mm ³	22	11	0.006
Neutropenia	<2000 cells/mm ³	95	97	n.s.
	<1000 cells/mm ³	84	78	n.s.
Leukopenia	<4000 cells/mm ³	97	97	n.s.
	<2000 cells/mm ³	76	67	n.s.
Anemia	<11g/dL	88	87	n.s.
	<8 g/dL	8	24	<0.001
Infections		18	21	n.s.
Bleeding		6	4	n.s.
Transfusions		25	33	n.s.
Gastrointestinal				
Nausea and vomiting		94	96	n.s.
Vomiting		82	91	0.007
Other GI side effects		40	48	n.s.
Neurologic				
Peripheral neuropathies		13	28	0.001
Ototoxicity		12	30	<0.001
Other sensory side effects		4	6	n.s.
Central neurotoxicity		23	29	n.s.
Renal				
Serum creatinine elevations		7	38	<0.001
Blood urea elevations		-	-	-
Hepatic				
Bilirubin elevations		5	3	n.s.
SGOT elevations		23	16	n.s.
Alkaline phosphatase elevations		29	20	n.s.
Electrolytes loss				
Sodium		-	-	-
Potassium		-	-	-
Calcium		-	-	-
Magnesium		58	77	<0.001
Other side effects				
Pain		54	52	n.s.
Asthenia		43	46	n.s.
Cardiovascular		23	30	n.s.
Respiratory		12	11	n.s.
Allergic		10	11	n.s.
Genitourinary		11	13	n.s.
Alopecia +		43	57	0.009
Mucositis		6	11	n.s.

* Values are in percent of evaluable patients

** n.s.= not significant, $p>0.05$

+ May have been affected by cyclophosphamide dosage delivered

Use as a Single Agent for Secondary Treatment of Advanced Ovarian Cancer: In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, Carboplatin Injection achieved six clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71 + weeks.

INDICATIONS AND USAGE

Initial Treatment of Advanced Ovarian Carcinoma: Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see **CLINICAL STUDIES**).

There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.

Secondary Treatment of Advanced Ovarian Carcinoma: Carboplatin Injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

CONTRAINDICATIONS

Carboplatin Injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds.

Carboplatin Injection should not be employed in patients with severe bone marrow depression or significant bleeding.

WARNINGS

Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.

Since anemia is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy.

Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial carboplatin dosages in these patients should be appropriately reduced (see **DOSAGE AND ADMINISTRATION**) and blood counts should be carefully monitored between courses. The use of carboplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.

Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents.

Carboplatin can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced emesis.

Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving carboplatin as secondary treatment.

Loss of vision, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.

As in the case of other platinum coordination compounds, allergic reactions to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy. (See **CONTRAINDICATIONS** and **ADVERSE REACTIONS: Allergic Reactions.**)

High dosages of carboplatin (more than four times the recommended dose) have resulted in severe abnormalities of liver function tests.

Carboplatin may cause fetal harm when administered to a pregnant woman. Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS

General: Needles or intravenous administration sets containing aluminum parts that may come in contact with carboplatin should not be used for the preparation

or administration of the drug. Aluminum can react with carboplatin causing precipitate formation and loss of potency.

Drug Interactions: The renal effects of nephrotoxic compounds may be potentiated by carboplatin.

Carcinogenesis, Mutagenesis, Impairment of Fertility: The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be carcinogenic. Carboplatin has been shown to be mutagenic both *in vitro* and *in vivo*. It has also been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. Secondary malignancies have been reported in association with multi-drug therapy.

Pregnancy: Pregnancy "Category D" (see **WARNINGS**).

Nursing Mothers: It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to carboplatin treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with carboplatin.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established (see **WARNINGS**; "Audiologic Toxicity").

Geriatric Use: Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients. In a combined database of 1942 patients (414 were ≥ 65 years of age) that received single agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Because renal function is often decreased in the elderly, renal function should be considered in the selection of carboplatin dosage (see **DOSAGE AND ADMINISTRATION**).

ADVERSE REACTIONS

For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see the **Comparative Toxicity** subsection of the **CLINICAL STUDIES** section.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER			
		First Line Combination Therapy* Percent	Second Line Single Agent Therapy* Percent
Bone Marrow			
Thrombocytopenia	<100,000/mm ³	66	62
	<50,000/mm ³	33	35
Neutropenia	<2000 cells/mm ³	96	67

Leukopenia	<1000 cells/mm ³	82	21
	<4000 cells/mm ³	97	85
	<2000 cells/mm ³	71	26
Anemia	<11g/dL	90	90
	<8 g/dL	14	21
Infections		16	5
Bleeding		8	5
Transfusions		35	44
Gastrointestinal			
Nausea and vomiting		93	92
Vomiting		83	81
Other GI side effects		46	21
Neurologic			
Peripheral neuropathies		15	6
Ototoxicity		12	1
Other sensory side effects		5	1
Central neurotoxicity		26	5
Renal			
Serum creatinine elevations		6	10
Blood urea elevations		17	22
Hepatic			
Bilirubin elevations		5	5
SGOT elevations		20	19
Alkaline phosphatase elevations		29	37
Electrolytes loss			
Sodium		10	47
Potassium		16	28
Calcium		16	31
Magnesium		61	43
Other side effects			
Pain		44	23
Asthenia		41	11
Cardiovascular		19	6
Respiratory		10	6
Allergic		11	2
Genitourinary		10	2
Alopecia		49	2
Mucositis		8	1

* **Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer:** Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see **CLINICAL STUDIES**).

Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.

** **Single Agent Use for the Secondary Treatment of Ovarian Cancer:** Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin.

In the narrative section that follows, the incidences of adverse events are based on data from 1893 patients with various types of tumors who received carboplatin as single-agent therapy.

Hematologic Toxicity: Bone marrow suppression is the dose-limiting toxicity of carboplatin. Thrombocytopenia with platelet counts below $50,000/\text{mm}^3$ occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below $1000/\text{mm}^3$ occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below $2,000/\text{mm}^3$ occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single-agent therapy. By day 28, 90% of patients have platelet counts above $100,000/\text{mm}^3$, 74% have neutrophil counts above $2,000/\text{mm}^3$; 67% have leukocyte counts above $4,000/\text{mm}^3$.

Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia.

The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia.

Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure to carboplatin. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients).

Bone marrow depression may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy.

Gastrointestinal Toxicity: Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting. Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for five consecutive days, was associated with less severe vomiting than the single dose intermittent schedule. Emesis was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%.

Neurologic Toxicity: Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin

appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with carboplatin. Clinical ototoxicity and othersensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics.

Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity.

Nephrotoxicity: Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced diuresis. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible.

Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy.

Hepatic Toxicity: The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%; and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported.

Electrolyte Changes: The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31 %, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms.

Allergic Reactions: Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions, have been similar in nature and severity to those reported with other platinum-containing compounds, i.e., rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Anaphylactic reactions have been reported as part of postmarketing surveillance (see WARNINGS). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy.

Injection Site Reactions: Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance. Necrosis associated with extravasation has also been reported.

Other Events: Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely.

Malaise, anorexia and hypertension have been reported as part of post-marketing surveillance.

OVERDOSAGE

There is no known antidote for Carboplatin Injection overdose. The anticipated complications of overdose would be secondary to bone marrow suppression and/or hepatic toxicity.

DOSAGE AND ADMINISTRATION

NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of Carboplatin Injection.

Single Agent Therapy: Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m² IV on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of Carboplatin Injection should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Combination Therapy with Cyclophosphamide: In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of:

Carboplatin Injection - 300 mg/m² IV on day 1 every four weeks for six cycles (alternatively see **Formula Dosing**).

Cyclophosphamide - 600 mg/m² IV on day 1 every four weeks for six cycles.

For directions regarding the use and administration of cyclophosphamide please refer to its package insert. (See **CLINICAL STUDIES**.)

Intermittent courses of Carboplatin Injection in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Dose Adjustment Recommendations: Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients.

The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.

Platelets	Neutrophils	Adjusted Dose* (From Prior Course)
>100,000	>2,000	125%
50-100,000	500-2,000	No Adjustment
<50,000	<500	75%

*Percentages apply to Carboplatin Injection as a single agent or to both Carboplatin Injection and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies.

Carboplatin Injection is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required.

Patients with Impaired Kidney Function: Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent Carboplatin Injection therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.

Baseline Creatinine Clearance	Recommended Dose on Day 1
41 - 59 mL/min	250 mg/m ²
16 - 40 mL/min	200 mg/m ²

The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment.

These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient's tolerance based on the degree of bone marrow suppression.

Formula Dosing: Another approach for determining the initial dose of Carboplatin Injection is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin. (See **CLINICAL PHARMACOLOGY**.) The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).

A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and Carboplatin Injection target area under the concentration versus time curve (AUC in mg/mL·min), has been proposed by Calvert. In these studies, GFR was measured by ⁵¹Cr-EDTA clearance.

CALVERT FORMULA FOR CARBOPLATIN DOSING

$$\text{Total Dose (mg)} = (\text{target AUC}) \times (\text{GFR} + 25)$$

Note: With the Calvert formula, the total dose of Carboplatin Injection is calculated in mg, not mg/m².

The target AUC of 4-6 mg/mL•min using single agent Carboplatin Injection appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single agent Carboplatin Injection administered to previously treated patients and the likelihood of developing toxicity.

% Actual Toxicity in Previously Treated Patients

AUC (mg/mL•min)	Gr 3 or Gr 4 Thrombocytopenia	Gr 3 or Gr 4 Leukopenia
4 to 5	16%	13%
6 to 7	33%	34%

Geriatric Dosing: Because renal function is often decreased in elderly patients, formula dosing of Carboplatin Injection based on estimates of GFR should be used in elderly patients to provide predictable plasma Carboplatin Injection AUCs and thereby minimize the risk of toxicity.

PREPARATION OF INTRAVENOUS SOLUTIONS

Carboplatin Injection 10 mg/mL is supplied as a Ready To Use (RTU) sterile solution in 5 mL, 15 mL, or 45 mL vials. Total content of carboplatin per vial is described in following table:

Vial Strength	Diluent Volume
50 mg	5 mL
150 mg	15 mL
450 mg	45 mL

Carboplatin Injection can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D₅W) or 0.9% Sodium Chloride Injection, USP.

STABILITY

Unopened vials of Carboplatin Injection are stable for the life indicated on the package when stored at 25°C (77°F) [excursions permitted to 15°-30°C (59°-86°F), see USP Controlled Room Temperature] and protected from light.

When further diluted, Carboplatin Injection solutions are stable for 8 hours at room temperature (25°C). Since no antibacterial preservative is contained in the formulation, it is recommended that Carboplatin Injection solutions be discarded 8 hours after dilution.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

HOW SUPPLIED

Carboplatin Injection 10 mg/mL sterile solution is available in the following presentations:

NDC 61703-339-18	50 mg/5mL vials, individually cartoned. (Blue flip-off seals)
NDC 61703-339-22	150 mg/15mL vials, individually cartoned. (Blue flip-off seals)
NDC 61703-339-50	450 mg vials, individually cartoned. (Blue flip-off seals)
NDC 61703-339-56	600 mg/60mL vials, individually cartoned. (Blue flip-off seals)

STORAGE

Store the unopened vials at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect unopened vials from light. Solutions for infusion should be discarded 8 hours after preparation.

HANDLING AND DISPOSAL

Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this subject have been published¹⁻⁷. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

REFERENCES

1. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.
2. AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. *JAMA* 1985; 253(11):1590-1592.
3. National Study Commission on Cytotoxic Exposure - Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
4. Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. *Med J Australia* 1983; 1:426-428.
5. Jones RB, et al: Safe Handling of Chemotherapeutic Agents: A Report From the Mount Sinai Medical Center. *CA-A Cancer Journal for Clinicians* 1983; (Sept/Oct) 258-263.
6. American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. *Am J Hosp Pharm* 1990; 47:1033-1049.
7. Controlling Occupational Exposure to Hazardous Drugs. (OSHA WORK-PRACTICE GUIDELINES). *Am J Health-Syst Pharm* 1995; 52:1669-1685.

Manufactured for:
Faulding Pharmaceutical Co.
a Mayne Group Company
Paramus, NJ 07652
By: Mayne Pharma Pty Ltd
Mulgrave VIC 3170
Australia

XXXXXX

April 2003

**Attachment
4**

ATTACHMENT 4

Paraplatin® Package Insert

PARAPLATIN® (carboplatin for injection)

WARNING

PARAPLATIN® (carboplatin for injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.


Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect.

Anaphylactic-like reactions to PARAPLATIN have been reported and may occur within minutes of PARAPLATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.

DESCRIPTION

PARAPLATIN® (carboplatin for injection) is supplied as a sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by intravenous infusion. Each vial contains equal parts by weight of carboplatin and mannitol.

Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0]-, (SP-4,2), and has the following structural formula:



Carboplatin is a crystalline powder with the molecular formula of C₆H₁₂N₂O₄Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5-7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide.

CLINICAL PHARMACOLOGY

Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.

In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 to 500 mg/m² of PARAPLATIN. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (N = 6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (N = 6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C_{max} values and areas under the plasma concentration vs. time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the range studied (300-500 mg/m²).

Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.

The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.

In patients with creatinine clearances below 60 mL/min the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. PARAPLATIN dosages should therefore be reduced in these patients (see DOSAGE AND ADMINISTRATION).

The primary determinant of PARAPLATIN clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see DOSAGE AND ADMINISTRATION) to provide predictable PARAPLATIN plasma AUCs should be used in elderly patients to minimize the risk of toxicity.

CLINICAL STUDIES

Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), 780 chemotherapy naive patients with advanced ovarian cancer were treated with PARAPLATIN or cisplatin, both in combination with cyclophosphamide every 28 days for six courses, before surgical reevaluation. The following results were obtained from both studies:

Comparative Efficacy:

Overview of Pivotal Trials

	NCIC	SWOG
Number of patients randomized	447	342
Median age (years)	60	62
Dose of cisplatin	75 mg/m ²	100 mg/m ²
Dose of carboplatin	300 mg/m ²	300 mg/m ²
Dose of CYTOXAN® (cyclophosphamide, USP)	600 mg/m ²	600 mg/m ²
Residual tumor < 2 cm (number of patients)	39% (174/447)	14% (49/342)

Clinical Response in Measurable Disease Patients

	NCIC	SWOG
Carboplatin (number of patients)	60% (48/80)	58% (48/83)
Cisplatin (number of patients)	58% (49/85)	43% (33/76)
95% C.I. of difference (Carboplatin - Cisplatin)	(-13.9%, 18.6%)	(-2.3%, 31.1%)

Pathologic Complete Response*

	NCIC	SWOG
Carboplatin (number of patients)	11% (24/224)	10% (17/171)
Cisplatin (number of patients)	15% (33/223)	10% (17/171)
95% C.I. of difference (Carboplatin - Cisplatin)	(-10.7%, 2.5%)	(-6.9%, 6.9%)

* 114 PARAPLATIN and 109 Cisplatin patients did not undergo second look surgery in NCIC study. 90 PARAPLATIN and 106 Cisplatin patients did not undergo second look surgery in SWOG study.

Progression-Free Survival (PFS)

	NCIC	SWOG
Median Carboplatin	59 weeks	49 weeks
Median Cisplatin	61 weeks	47 weeks
2-year PFS*		
Carboplatin	31%	21%
Cisplatin	31%	21%
95% C.I. of difference (Carboplatin - Cisplatin)	(-9.3, 8.7)	(-9.0, 9.4)
3-year PFS*		
Carboplatin	19%	8%
Cisplatin	23%	14%
95% C.I. of difference (Carboplatin - Cisplatin)	(-11.5, 4.5)	(-14.1, 0.3)
Hazard Ratio**	1.10	1.02
95% C.I.	(0.89, 1.35)	(0.81, 1.29)

* Kaplan-Meier Estimates

Unrelated deaths occurring in the absence of progression were counted as events (progression) in this analysis.

** Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.

Survival

	NCIC	SWOG
Median Carboplatin	110 weeks	86 weeks
Median Cisplatin	99 weeks	79 weeks
2-year Survival*		
Carboplatin	51.9%	40.2%
Cisplatin	48.4%	39.0%
95% C.I. of difference (Carboplatin - Cisplatin)	(-6.2, 13.2)	(-9.8, 12.2)
3-year Survival*		
Carboplatin	34.6%	18.3%
Cisplatin	33.1%	24.9%
95% C.I. of difference (Carboplatin - Cisplatin)	(-7.7, 10.7)	(-15.9, 2.7)
Hazard Ratio**	0.98	1.01
95% C.I.	(0.78, 1.23)	(0.78, 1.30)

* Kaplan-Meier Estimates

** Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.

Comparative Toxicity: The pattern of toxicity exerted by the PARAPLATIN (carboplatin for injection)-containing regimen was significantly different from that of the cisplatin-containing combinations. Differences between the two studies may be explained by different cisplatin dosages and by different supportive care.

The PARAPLATIN-containing regimen induced significantly more thrombocytopenia and, in one study, significantly more leukopenia and more need for transfusional support. The cisplatin-containing regimen produced significantly more anemia in one study. However, no significant differences occurred in incidences of infections and hemorrhagic episodes.

Non-hematologic toxicities (emesis, neurotoxicity, ototoxicity, renal toxicity, hypomagnesemia, and alopecia) were significantly more frequent in the cisplatin-containing arms.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY

	PARAPLATIN Arm Percent*	Cisplatin Arm Percent*	P-Values**
Bone Marrow			
Thrombocytopenia < 100,000/mm ³	70	29	< 0.001
< 50,000/mm ³	41	6	< 0.001
Neutropenia < 2,000 cells/mm ³	97	96	n.s.
< 1,000 cells/mm ³	81	79	n.s.
Leukopenia < 4,000 cells/mm ³	98	97	n.s.
< 2,000 cells/mm ³	68	52	0.001
Anemia < 11 g/dL	91	91	n.s.
< 8 g/dL	18	12	n.s.
Infections	14	12	n.s.
Bleeding	10	4	n.s.
Transfusions	42	31	0.018
Gastrointestinal			
Nausea and vomiting	93	98	0.010
Vomiting	84	97	< 0.001
Other GI side effects	50	62	0.013
Neurologic			
Peripheral neuropathies	16	42	< 0.001
Ototoxicity	13	33	< 0.001
Other sensory side effects	6	10	n.s.
Central neurotoxicity	28	40	0.009
Renal			
Serum creatinine elevations	5	13	0.006
Blood urea elevations	17	31	< 0.001
Hepatic			
Bilirubin elevations	5	3	n.s.
SGOT elevations	17	13	n.s.
Alkaline phosphatase elevations	-	-	-
Electrolytes loss			
Sodium	10	20	0.005
Potassium	16	22	n.s.
Calcium	16	19	n.s.
Magnesium	63	88	< 0.001
Other side effects			
Pain	36	37	n.s.
Asthenia	40	33	n.s.
Cardiovascular	15	19	n.s.
Respiratory	8	9	n.s.
Allergic	12	9	n.s.
Genitourinary	10	10	n.s.
Alopecia+	50	62	0.017
Mucositis	10	9	n.s.

* Values are in percent of evaluable patients

** n.s. = not significant, p > 0.05

+ May have been affected by cyclophosphamide dosage delivered

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY

	PARAPLATIN Arm Percent*	Cisplatin Arm Percent*	P-Values**
Bone Marrow			
Thrombocytopenia < 100,000/mm ³	59	35	< 0.001
< 50,000/mm ³	22	11	0.006
Neutropenia < 2,000 cells/mm ³	95	97	n.s.
< 1,000 cells/mm ³	84	78	n.s.
Leukopenia < 4,000 cells/mm ³	97	97	n.s.
< 2,000 cells/mm ³	76	67	n.s.
Anemia < 11 g/dL	88	87	n.s.
< 8 g/dL	8	24	< 0.001
Infections	8	21	n.s.
Bleeding	6	4	n.s.
Transfusions	25	33	n.s.
Gastrointestinal			
Nausea and vomiting	94	96	n.s.
Vomiting	82	91	0.007
Other GI side effects	40	48	n.s.
Neurologic			
Peripheral neuropathies	13	28	0.001
Ototoxicity	12	30	< 0.001
Other sensory side effects	4	6	n.s.
Central neurotoxicity	23	29	n.s.
Renal			
Serum creatinine elevations	7	38	< 0.001
Blood urea elevations	-	-	-
Hepatic			
Bilirubin elevations	5	3	n.s.
SGOT elevations	23	16	n.s.
Alkaline phosphatase elevations	29	20	n.s.
Electrolytes loss			
Sodium	-	-	-
Potassium	-	-	-
Calcium	-	-	-
Magnesium	58	77	< 0.001
Other side effects			
Pain	54	52	n.s.
Asthenia	43	46	n.s.
Cardiovascular	23	30	n.s.
Respiratory	12	11	n.s.
Allergic	10	11	n.s.
Genitourinary	11	13	n.s.
Alopecia+	43	57	0.009
Mucositis	6	11	n.s.

* Values are in percent of evaluable patients

** n.s. = not significant, p > 0.05

+ May have been affected by cyclophosphamide dosage delivered

Use as a Single Agent for Secondary Treatment of Advanced Ovarian Cancer: In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, PARAPLATIN (carboplatin for injection) achieved six clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.

INDICATIONS

Initial Treatment of Advanced Ovarian Carcinoma: PARAPLATIN is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide (CYTOXAN®), two randomized controlled studies conducted by the NCIC and SWOG with PARAPLATIN vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES).

There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes; the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.

Secondary Treatment of Advanced Ovarian Carcinoma: PARAPLATIN is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

CONTRAINDICATIONS

PARAPLATIN is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds, or mannitol. PARAPLATIN should not be employed in patients with severe bone marrow depression or significant bleeding.

WARNINGS

Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during PARAPLATIN treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent PARAPLATIN. In general, single intermittent courses of PARAPLATIN should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.

Since anemia is cumulative, transfusions may be needed during treatment with PARAPLATIN, particularly in patients receiving prolonged therapy.

Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial PARAPLATIN dosages in these patients should be appropriately reduced (see DOSAGE AND ADMINISTRATION) and blood counts should be carefully monitored between courses. The use of PARAPLATIN in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.

PARAPLATIN has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiological toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when PARAPLATIN was administered at higher than recommended doses in combination with other ototoxic agents.

PARAPLATIN can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of PARAPLATIN, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced emesis.

Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving PARAPLATIN as secondary treatment.

Loss of vision, which can be complete for light and colors, has been reported after the use of PARAPLATIN (carboplatin for injection) with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.

As in the case of other platinum coordination compounds, allergic reactions to PARAPLATIN have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of allergic reactions including anaphylaxis in patients newly exposed to platinum therapy. (See **CONTRAINDICATIONS** and **ADVERSE REACTIONS: Allergic Reactions**.)

A dosages of PARAPLATIN (more than four times the recommended dose) have resulted in severe abnormalities of liver function tests.

PARAPLATIN may cause fetal harm when administered to a pregnant woman. PARAPLATIN has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS

General: Needles or intravenous administration sets containing aluminum parts that may come in contact with PARAPLATIN should not be used for the preparation or administration of the drug. Aluminum can react with carboplatin causing precipitate formation and loss of potency.

Drug Interactions: The renal effects of nephrotoxic compounds may be potentiated by PARAPLATIN.

Carcinogenesis, Mutagenesis, Impairment of Fertility: The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be carcinogenic. Carboplatin has been shown to be mutagenic both *in vitro* and *in vivo*. It has also been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. Secondary malignancies have been reported in association with multi-drug therapy.

Pregnancy: Pregnancy Category D. (See **WARNINGS**.)

Nursing Mothers: It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to PARAPLATIN treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with PARAPLATIN.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established. (See **WARNINGS**, "Audiologic Toxicity".)

Geriatric Use: Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients. In a combined database of 1942 patients (414 were ≥65 years of age) that received single agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Because renal function is often decreased in the elderly, renal function should be considered in the selection of PARAPLATIN dosage. (See **DOSE AND ADMINISTRATION**.)

ADVERSE REACTIONS

For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see the **Comparative Toxicity** subsection of the **CLINICAL STUDIES** section.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER

	First Line Combination Therapy* Percent	Second Line Single Agent Therapy** Percent
Bone Marrow		
Thrombocytopenia	< 100,000/mm ³ 66	62
	< 50,000/mm ³ 33	35
Neutropenia	< 2,000 cells/mm ³ 96	67
	< 1,000 cells/mm ³ 82	21
Leukopenia	< 4,000 cells/mm ³ 97	85
	< 2,000 cells/mm ³ 71	26
Anemia	< 11 g/dL 90	90
	< 8 g/dL 14	21
Infections	16	5
Bleeding	8	5
Transfusions	35	44
Gastrointestinal		
Nausea and vomiting	93	92
Vomiting	83	81
Other GI side effects	46	21
Neurologic		
Peripheral neuropathies	15	6
Ototoxicity	12	1
Other sensory side effects	5	1
Central neurotoxicity	26	5
Renal		
Serum creatinine elevations	6	10
Blood urea elevations	17	22
Hepatic		
Bilirubin elevations	5	5
SGOT elevations	20	19
Alkaline phosphatase elevations	29	37
Electrolytes loss		
Sodium	10	47
Potassium	16	28
Calcium	16	31
Magnesium	61	43
Other side effects		
Pain	44	23
Asthenia	41	11
Cardiovascular	19	6
Respiratory	10	6
Allergic	11	2
Genitourinary	10	2
Alopecia	49	2
Mucositis	8	1

*See with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with PARAPLATIN and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see **CLINICAL STUDIES**).

Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.

**Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent PARAPLATIN.

In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received PARAPLATIN (carboplatin for injection) as single-agent therapy.

Hematologic Toxicity: Bone marrow suppression is the dose-limiting toxicity of PARAPLATIN. Thrombocytopenia with platelet counts below 50,000/mm³ occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below 1,000/mm³ occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below 2,000/mm³ occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single-agent therapy. By day 28, 90% of patients have platelet counts above 100,000/mm³; 74% have neutrophil counts above 2,000/mm³; 67% have leukocyte counts above 4,000/mm³.

Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia.

The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with PARAPLATIN, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia.

Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure to PARAPLATIN. Transfusions have been administered to 26% of the patients treated with PARAPLATIN (44% of previously treated ovarian cancer patients).

Bone marrow depression may be more severe when PARAPLATIN is combined with other bone marrow suppressing drugs or with radiotherapy.

Gastrointestinal Toxicity: Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting. Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of PARAPLATIN, either by continuous 24-hour infusion or by daily pulse doses given for five consecutive days, was associated with less severe vomiting than the single dose intermittent schedule. Emesis was increased when PARAPLATIN was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%.

Neurologic Toxicity: Peripheral neuropathies have been observed in 4% of the patients receiving PARAPLATIN (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with PARAPLATIN. Clinical ototoxicity and other sensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics.

Although the overall incidence of peripheral neurologic side effects induced by PARAPLATIN is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity.

Nephrotoxicity: Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced diuresis. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible.

Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving PARAPLATIN, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during PARAPLATIN therapy.

Hepatic Toxicity: The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%, and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of PARAPLATIN and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported.

Electrolyte Changes: The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31%, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely administered concomitantly with PARAPLATIN, and these electrolyte abnormalities were rarely associated with symptoms.

Allergic Reactions: Hypersensitivity to PARAPLATIN has been reported in 2% of the patients. These allergic reactions have been similar in nature and severity to those reported with other platinum-containing compounds, i.e., rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Anaphylactic reactions have been reported as part of postmarketing surveillance (see **WARNINGS**). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy.

Injection Site Reactions: Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance. Necrosis associated with extravasation has also been reported.

Other Events: Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely.

Malaise, anorexia and hypertension have been reported as part of post-marketing surveillance.

OVERDOSAGE

There is no known antidote for PARAPLATIN overdosage. The anticipated complications of overdosage would be secondary to bone marrow suppression and/or hepatic toxicity.

DOSE AND ADMINISTRATION

NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of PARAPLATIN.

Single Agent Therapy: PARAPLATIN (carboplatin for injection), as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m² I.V. on day 1 every 4 weeks (alternatively see **Formula Dosing**). In general, however, single intermittent courses of PARAPLATIN should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Combination Therapy with Cyclophosphamide: In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of:

PARAPLATIN—300 mg/m² I.V. on day 1 every four weeks for six cycles (alternatively see **Formula Dosing**).

Cyclophosphamide (CYTOXAN®)—600 mg/m² I.V. on day 1 every four weeks for six cycles. For directions regarding the use and administration of cyclophosphamide (CYTOXAN) please refer to its package insert. (See **CLINICAL STUDIES**.)

Intermittent courses of PARAPLATIN in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Dose Adjustment Recommendations: Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients.

The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.

Platelets	Neutrophils	Adjusted Dose* (From Prior Course)
> 100,000	> 2,000	125%
50-100,000	500-2,000	No Adjustment
< 50,000	< 500	75%

*Percentages apply to PARAPLATIN as a single agent or to both PARAPLATIN and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies.

PARAPLATIN is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required.

Patients with Impaired Kidney Function: Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent PARAPLATIN therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.

Baseline Creatinine Clearance	Recommended Dose on Day 1
41-59 mL/min	250 mg/m ²
16-40 mL/min	200 mg/m ²

The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment.

These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient's tolerance based on the degree of bone marrow suppression.

Formula Dosing: Another approach for determining the initial dose of PARAPLATIN is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin. (See **CLINICAL PHARMACOLOGY**.) The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).

A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and PARAPLATIN target area under the concentration versus time curve (AUC in mg/mL·min), has been proposed by Calvert. In these studies, GFR was measured by ⁵¹Cr-EDTA clearance.

CALVERT FORMULA FOR CARBOPLATIN DOSING	
Total Dose (mg) = (target AUC) x (GFR + 25)	
Note: With the Calvert formula, the total dose of PARAPLATIN is calculated in mg, not mg/m ² .	

The target AUC of 4-6 mg/mL·min using single agent PARAPLATIN appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single agent PARAPLATIN administered to previously treated patients and the likelihood of developing toxicity.

% Actual Toxicity in Previously Treated Patients		
AUC (mg/mL·min)	Gr 3 or Gr 4 Thrombocytopenia	Gr 3 or Gr 4 Leukopenia
4 to 5	16%	13%
6 to 7	33%	34%

Geriatric Dosing: Because renal function is often decreased in elderly patients, formula dosing of PARAPLATIN based on estimates of GFR should be used in elderly patients to provide predictable plasma PARAPLATIN AUC and thereby minimize the risk of toxicity.

PREPARATION OF INTRAVENOUS SOLUTIONS

Immediately before use, the content of each vial must be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D₅W), or 0.9% Sodium Chloride Injection, USP, according to the following schedule:

Vial Strength	Diluent Volume
50 mg	5 mL
150 mg	15 mL
450 mg	45 mL

These dilutions all produce a carboplatin concentration of 10 mg/mL. PARAPLATIN can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D₅W) or 0.9% Sodium Chloride Injection, USP.

STABILITY

Unopened vials of PARAPLATIN are stable for the time indicated on the package when stored at 25°C (77°F) [excursions permitted to 15°-30°C (59°-86°F)], see USP Controlled Room Temperature and protected from light.

When prepared as directed, PARAPLATIN solutions are stable for 8 hours at room temperature (25°C). Since no antibacterial preservative is contained in the formulation, it is recommended that PARAPLATIN solutions be discarded 8 hours after dilution.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

HOW SUPPLIED

PARAPLATIN® (carboplatin for injection)

- NDC 0015-3213-30 50 mg vials, individually cartoned, shelf packs of 10 cartons, 10 shelf packs per case. (Yellow flip-off seals)
- NDC 0015-3214-30 150 mg vials, individually cartoned, shelf packs of 10 cartons, 10 shelf packs per case. (Violet flip-off seals)
- NDC 0015-3215-30 450 mg vials, individually cartoned, shelf packs of 10 cartons, 10 shelf packs per case. (Blue flip-off seals)

STORAGE

Store the unopened vials at 25° C (77° F); excursions permitted to 15°-30° C (59°-86° F) [see USP Controlled Room Temperature]. Protect unopened vials from light. Solutions for infusion should be discarded 8 hours after preparation.

HANDLING AND DISPOSAL

Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this subject have been published.^{1,2} There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

REFERENCES

1. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.
2. AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. *JAMA* 1985; 253(11):1590-1592.
3. National Study Commission on Cytotoxic Exposure—Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
4. Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. *Med J Australia* 1983; 1:426-428.
5. Jones RB, et al: Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. *CA—A Cancer Journal for Clinicians* 1983; (Sept/Oct)258-263.
6. American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. *Am J Hosp Pharm* 1990; 47:1033-1049.
7. Controlling Occupational Exposure to Hazardous Drugs. (OSHA WORK PRACTICE GUIDELINES). *Am J Health-Syst Pharm* 1995; 52:1669-1685.

U.S. Patent Nos. 4,140,707
4,657,927



Bristol-Myers Squibb Company
Princeton, NJ 08543
U.S.A.

K2-B001-10-01
1080187A4

3213DIM-14
Revised June 2001